Compare TKR & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKR | QGEN |
|---|---|---|
| Founded | 1899 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 9.0B |
| IPO Year | 1994 | 1998 |
| Metric | TKR | QGEN |
|---|---|---|
| Price | $115.22 | $48.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 16 |
| Target Price | ★ $144.20 | $48.13 |
| AVG Volume (30 Days) | 765.7K | ★ 2.3M |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | 1.27% | ★ 5.64% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.81 | N/A |
| Revenue | ★ $80,100,000.00 | N/A |
| Revenue This Year | $5.82 | $2.16 |
| Revenue Next Year | $3.10 | $5.06 |
| P/E Ratio | $62.48 | ★ $24.01 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $73.62 | $32.53 |
| 52 Week High | $146.37 | $57.82 |
| Indicator | TKR | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 46.13 | 65.33 |
| Support Level | $114.58 | $46.72 |
| Resistance Level | $123.93 | $49.86 |
| Average True Range (ATR) | 2.71 | 1.28 |
| MACD | 0.06 | 0.31 |
| Stochastic Oscillator | 36.89 | 63.32 |
The Timken Co designs and manages a portfolio of engineered bearings and industrial motion products, and provides related services. The various products offered by the company include ball bearings, plain bearings, tapered roller bearings, housed bearings, linear guides, telescopic rails, lubrication systems, agricultural conveyor chains, couplings, brakes, seals, etc. These products are offered through brands like Timken, GGB, Philadelphia Gear, Cone Drive, CGI, and Rollon, among others. The company has two reportable segments: Engineered Bearings, which generates the maximum revenue, and Industrial Motion. Geographically, the company generates maximum revenue from the United States, followed by Europe, Middle East and Africa (EMEA), Asia-Pacific, and the other regions of the Americas.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).